Cargando…
Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial
BACKGROUND: The efficacy of the unified protocol of the transdiagnostic treatment for emotional disorders (UP) has been poorly studied in patients with depressive disorders. This study aimed to examine the efficacy of UP for improving depressive symptoms in patients with depressive and/or anxiety-re...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235654/ https://www.ncbi.nlm.nih.gov/pubmed/37449485 http://dx.doi.org/10.1017/S0033291721005067 |
_version_ | 1785052735798771712 |
---|---|
author | Ito, Masaya Horikoshi, Masaru Kato, Noriko Oe, Yuki Fujisato, Hiroko Yamaguchi, Keiko Nakajima, Shun Miyamae, Mitsuhiro Toyota, Ayaka Okumura, Yasuyuki Takebayashi, Yoshitake |
author_facet | Ito, Masaya Horikoshi, Masaru Kato, Noriko Oe, Yuki Fujisato, Hiroko Yamaguchi, Keiko Nakajima, Shun Miyamae, Mitsuhiro Toyota, Ayaka Okumura, Yasuyuki Takebayashi, Yoshitake |
author_sort | Ito, Masaya |
collection | PubMed |
description | BACKGROUND: The efficacy of the unified protocol of the transdiagnostic treatment for emotional disorders (UP) has been poorly studied in patients with depressive disorders. This study aimed to examine the efficacy of UP for improving depressive symptoms in patients with depressive and/or anxiety-related disorders. METHODS: This assessor-blinded, randomized, 20-week, parallel-group, superiority study compared the efficacy of the UP with treatment-as-usual (UP-TAU) v. wait-list with treatment-as-usual (WL-TAU). Patients diagnosed with depressive and/or anxiety disorders and with depressive symptoms participated. The primary outcome was depressive symptoms assessed by GRID-Hamilton depression rating scale (GRID-HAMD) at 21 weeks. The secondary outcomes included assessor-rated anxiety symptoms, severity and improvement of clinical global impression, responder and remission status, and loss of principal diagnosis. RESULTS: In total, 104 patients participated and were subjected to intention-to-treat analysis [mean age = 37.4, s.d. = 11.5, 63 female (61%), 54 (51.9%) with a principal diagnosis of depressive disorders]. The mean GRID-HAMD scores in the UP-TAU and WL-TAU groups were 16.15 (s.d. = 4.90) and 17.06 (s.d. = 6.46) at baseline and 12.14 (s.d. = 5.47) and 17.34 (s.d. = 5.78) at 21 weeks, with a significant adjusted mean change difference of −3.99 (95% CI −6.10 to −1.87). Patients in the UP-TAU group showed significant superiority in anxiety and clinical global impressions. The improvement in the UP-TAU group was maintained in all outcomes at 43 weeks. No serious adverse events were observed in the UP-TAU group. CONCLUSIONS: The UP is an effective approach for patients with depressive and/or anxiety disorders. |
format | Online Article Text |
id | pubmed-10235654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102356542023-06-03 Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial Ito, Masaya Horikoshi, Masaru Kato, Noriko Oe, Yuki Fujisato, Hiroko Yamaguchi, Keiko Nakajima, Shun Miyamae, Mitsuhiro Toyota, Ayaka Okumura, Yasuyuki Takebayashi, Yoshitake Psychol Med Original Article BACKGROUND: The efficacy of the unified protocol of the transdiagnostic treatment for emotional disorders (UP) has been poorly studied in patients with depressive disorders. This study aimed to examine the efficacy of UP for improving depressive symptoms in patients with depressive and/or anxiety-related disorders. METHODS: This assessor-blinded, randomized, 20-week, parallel-group, superiority study compared the efficacy of the UP with treatment-as-usual (UP-TAU) v. wait-list with treatment-as-usual (WL-TAU). Patients diagnosed with depressive and/or anxiety disorders and with depressive symptoms participated. The primary outcome was depressive symptoms assessed by GRID-Hamilton depression rating scale (GRID-HAMD) at 21 weeks. The secondary outcomes included assessor-rated anxiety symptoms, severity and improvement of clinical global impression, responder and remission status, and loss of principal diagnosis. RESULTS: In total, 104 patients participated and were subjected to intention-to-treat analysis [mean age = 37.4, s.d. = 11.5, 63 female (61%), 54 (51.9%) with a principal diagnosis of depressive disorders]. The mean GRID-HAMD scores in the UP-TAU and WL-TAU groups were 16.15 (s.d. = 4.90) and 17.06 (s.d. = 6.46) at baseline and 12.14 (s.d. = 5.47) and 17.34 (s.d. = 5.78) at 21 weeks, with a significant adjusted mean change difference of −3.99 (95% CI −6.10 to −1.87). Patients in the UP-TAU group showed significant superiority in anxiety and clinical global impressions. The improvement in the UP-TAU group was maintained in all outcomes at 43 weeks. No serious adverse events were observed in the UP-TAU group. CONCLUSIONS: The UP is an effective approach for patients with depressive and/or anxiety disorders. Cambridge University Press 2023-05 2022-01-10 /pmc/articles/PMC10235654/ /pubmed/37449485 http://dx.doi.org/10.1017/S0033291721005067 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
spellingShingle | Original Article Ito, Masaya Horikoshi, Masaru Kato, Noriko Oe, Yuki Fujisato, Hiroko Yamaguchi, Keiko Nakajima, Shun Miyamae, Mitsuhiro Toyota, Ayaka Okumura, Yasuyuki Takebayashi, Yoshitake Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial |
title | Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial |
title_full | Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial |
title_fullStr | Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial |
title_full_unstemmed | Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial |
title_short | Efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial |
title_sort | efficacy of the unified protocol for transdiagnostic cognitive-behavioral treatment for depressive and anxiety disorders: a randomized controlled trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235654/ https://www.ncbi.nlm.nih.gov/pubmed/37449485 http://dx.doi.org/10.1017/S0033291721005067 |
work_keys_str_mv | AT itomasaya efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT horikoshimasaru efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT katonoriko efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT oeyuki efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT fujisatohiroko efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT yamaguchikeiko efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT nakajimashun efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT miyamaemitsuhiro efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT toyotaayaka efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT okumurayasuyuki efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial AT takebayashiyoshitake efficacyoftheunifiedprotocolfortransdiagnosticcognitivebehavioraltreatmentfordepressiveandanxietydisordersarandomizedcontrolledtrial |